NMN pauka (1094-61-7)

April 7, 2020

ʻO Cofttek ka mea hana NMN pauka maikaʻi loa ma Kina. Loaʻa i kā mākou hale hana kahi ʻōnaehana hana hoʻopihapiha piha (ISO9001 & ISO14001), me ka mana hana i kēlā me kēia mahina o 2400kg.

 


Kūlana: I ka Production Production
Mokuna: 1kg / ʻeke, 25kg / Drum

NMN pauka (1094-61-7) wikiō

 

ʻO ka pauma NMN Snāʻike

Name: β-Nicotinamide Kaiwau (NMN)
CAS: 1094-61-7
Purity 98%
Kaulike Molecular: C11H15N2O8P
Kaumaha Molecular: 334.2208 g / mole
Wahi Manaʻo: > 96 ° C
Inoa inoa inoa inoa: ((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate
Hōʻuluʻulu Manaʻo: Nicotinamide Mononucleotide; NMN; β-NMN; β-Nicotinamide mononucleotide
InChI Key: DAYLJWODMCOQEW-TURQNECASA-N
Half Ola: N / A
Palekana: Hoʻopau maikaʻiʻia i DMSO, Methanol, Wai
Ke kūlana Mana: 0 - 4 C no ka wā pōkole (mau lā a i mau pule), a i ʻole -20 C no ka wā lōʻihi (mahina)
noi: ʻO Nicotinamide mononucleotide (NMN) kahi hānō o ka niacin B-vitamin e hoʻomaikaʻi nui ana i ke olakino a ka lōʻihi e ka lawelawe ʻana ma NAD +, kahi pūhui e hoʻokō nui ana i ka hana o ka ikehu, metabolism, a me ka haʻiʻike o ka gen i loko o ke kino.
ʻAno: ʻO ka pauma

 

NMN (1094-61-7) NMR Spectrum

NMN (1094-61-7) - NMR Spectrum

Inā makemake ʻoe iā COA, MSDS, HNMR no kēlā me kēia ʻōhua o ka huahana a me nā ʻike ʻē aʻe, e ʻoluʻolu e leka uila i kā mākou luna kūʻai kūʻai.

 

He aha ia β-Nicotinamide Mononucleotide (NMN) CAS 1094-61-7?

ʻO Nicotinamide Mononucleotide, i ʻike ʻia ((NMN "a me" β-NMN ") kahi nucleotide i loaʻa mai ka ribose a me ka nicotinamide E like me ka nicotinamide riboside, ʻo NMN kahi huaʻōlelo o ka niacin, a he mau ʻenima nā kānaka e hiki ke hoʻohana i ka NMN e hana i ka nicotinamide adenine dinucleotide ( NADH). No ka mea ʻo NADH kahi cofactor no nā kaʻina hana i loko o mitochondria, no nā sirtuins, a no PARP, ua aʻo ʻia ʻo NMN i nā hiʻohiʻona holoholona e like me ka neuroprotective a me ka anti-ʻelemakule agena.

 

benefits-Nicotinamide Mononucleotide (NMN) CAS 1094-61-7 mau pōmaikaʻi

Ua hōʻike ʻia nā noiʻi anti-kahiko i ka hoʻohui ʻia me NMN, kahi kī nui NAD + waena, e hana i ka hoʻēmi ʻana i ka hoʻoneʻe metabola pili i ka makahiki a me ka hoʻolohi i ka holomua o nā maʻi pili i ka makahiki. Loaʻa i ka NMN nā hopena maikaʻi loa i ka hana ʻana o ka ikehu ma ka pae cellular, hoʻomaikaʻi i ka hoʻomanawanui i ka glucose, hōʻemi i ka hoʻowalewale, kōkua i ka mālama ʻana i ka ʻōnaehana uila, hana hou i ka DNA, a loaʻa nā hopena kūpono e mālama i ka hana kognitive. Ua hōʻike pū ʻia ʻo NMN i hiki ke lilo i ka mea lapaʻau e kūʻē i nā maʻi neurodegenerative o ke ʻano o ka wā kahiko. Hoʻopili ia me ka NMN ka waiwai i ka mālama ʻana i ka hoʻomanawanui a me ka neʻe ʻana. Ke mālama nei i nā hana o kēia mau ʻāpana ʻokoʻa ma ke kino e hāpai i ka olakino a lōʻihi a lōʻihi hoʻi ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola ma ka holomua.

 

β-Nicotinamide Mononucleotide (NMN) CAS 1094-61-7 Hoʻolaha i ka hana?

ʻO β-Nicotinamide Mononucleotide (NMN) kahi waena o NAD + biosynthesis i hana ʻia mai ka nicotinamide ma o ka nicotinamide phosphoribosyltransferase (NAMPT) a kapa ʻia ʻo NMN a i ʻole rikideide nicotinamide. I nā noi hou o nā noi NMN i ka pale a me ka ʻike ʻana i nā maʻi kū i ka makahiki e like me ka maʻi diabetes, maʻi neurodegenerative, maʻi puʻuwai a pēlā aku, ua lilo ia i hoʻokahi o nā biomarkers ʻoi loa loa e pili ana i ke kūkākūkā no ka anti-age, i kēia mau lā.

 

β-Nicotinamide Mononucleotide (NMN) CAS 1094-61-7 noi

β-Nicotinamide Mononucleotide (NMN) i loaʻa nā hopena maikaʻi loa i ka metabolism ma loko o ke kino holoʻokoʻa, e komo pū ai i nā hopena maikaʻi i ka ʻūlā ʻana o ka ʻōpū, ka hana ʻana o ka ʻōpū, ka pale ʻana o ka iwi, ka hana ʻana i ka naʻau, ka naʻau ʻokoʻa, ka hana naʻau, ke kaumaha o ke kino, a me nā pae hana.

 

NMN ka lehu no ka kuai(Ma hea e kūʻai ai powder-Nicotinamide Mononucleotide (NMN) pauka i ka ʻōlapa)

ʻOliʻoli kā mākou ʻoihana i nā pilina lōʻihi e ko mākou mea kūʻai aku no ka mea ke nānā aku nei mākou i ka lawelawe o ka mea kūʻai aku a hāʻawi i nā huahana maikaʻi. Inā makemake ʻoe i kā mākou huahana, maʻalahi mākou me ka hoʻokaʻawale ʻana i nā kauoha e kūpono i kāu pono kūikawā a me ko mākou wikiwiki wikiwiki i nā kauoha e hōʻoia ʻoe e hoʻāʻo nui i kā mākou huahana i ka manawa. Hoʻomaopopo pū mākou i nā lawelawe i hoʻohui ʻia. Loaʻa mākou i nā nīnau a me ka ʻike e kākoʻo i kāu ʻoihana.

He mea hana loea mākou ʻo β-Nicotinamide Mononucleotide (NMN) no nā makahiki he nui, hoʻolako mākou i nā huahana me ke kumu kūʻai, a ʻo kā mākou huahana he mea kiʻekiʻe loa a hoʻomalu ʻia ma ka hōʻoia ʻana kūʻokoʻa, e hōʻoia kūleʻa ʻo ia no ka ʻai ʻana ma ka honua.

 

E hoʻomaopopo '

  • Kiss T, Balasubramanian P, Valcarcel-Ares MN, Tarantini S, Yabluchanskiy A, Csipo T, Lipecz A, Reglodi D, Zhang XA, Bari F, Farkas E, Csiszar A, Ungvari Z. Nicotinamide mononucleotide (NMN) treatment attenuates oxidative stress a hoʻopakele i ka maʻi angiogenic ma nā selama endothelial cerebromicrovascular kahiko: kahi hana kūlohelohe no ka pale ʻana o ka maʻi cognitive cognitive. Kālaiʻu. 2019 May 29. doi: 10.1007 / s11357-019-00074-2. PubMed PMID: 31144244.
  • Lukacs M, Gilley J, Zhu Y, Orsomando G, Angeletti C, Liu J, Yang X, Park J, Hopkin RJ, Coleman MP, Zhai RG, Stottmann RW. ʻO ka hana biallelic loss-of-function mutations ma nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) i nā kukuna ʻelua me ka hana fetals akinesia deformation. Exp Neurol. 2019 Mei 25: 112961. doi: 10.1016 / j.expneurol.2019.112961.PubMed PMID: 31136762.
  • Grozio A, Mills KF, Yoshino J, Bruzzone S, Sociali G, Tokizane K, Lei HC, Cunningham R, Sasaki Y, Migaud ME, Imai SI. ʻO Slc12a8 he mea hoʻopuka mononucleotide molotinamide. Nat Metab. 2019 Jan; 1 (1): 47-57. doi: 10.1038 / s42255-018-0009-4. Epub 2019 Jan 7. PubMed PMID: 31131364; PubMed Central PMCID: PMC6530925.